1. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009;15(5):627-631. 2. National Multiple Sclerosis Society. https://www.nationalmssociety.org/. Published August 27, 2018. Accessed April 19, 2019. 3. Belman AL, Krupp LB, Olsen CS, et al. Characteristics of children and adolescents with multiple sclerosis. Pediatrics. 2016;138(1):e20160120. 4. Ghezzi A, Baroncini D, Zaffaroni M, Comi G. Pediatric versus adult MS: similar or different? Mult Scler Demyelinating Disord. Published online May 7, 2017. doi:10.1186/s40893-017-0022-6. 5. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603-2613. 6. Pena JA, Lotze TE. Pediatric multiple sclerosis: current concepts and consensus definitions. Autoimmune Dis. 2013;2013:673947. 7. Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18(1):27. doi:10.1186/s12883-018-1026-3. 8. Lulu S, Graves J, Waubant E. Menarche increases relapse risk in pediatric multiple sclerosis. Mult Scler. 2016;22(2):193-200. 9. Chabas D, Green AJ, Waubant E. Pediatric multiple sclerosis. NeuroRx. 2006;3(2):264-275. 10. Venkateswaran S, Banwell B. Pediatric multiple sclerosis. Neurologist. 2010;16(2):92-105. 11. Mellen Center Approach: Pediatric Onset Multiple Sclerosis. Cleveland Clinic. https://my.clevelandclinic.org/-/scassets/files/org/neurological/multipl.... Accessed April 19, 2019. 12. Ghezzi A. Pediatric multiple sclerosis: epidemiology, clinical aspects, diagnosis and treatment. Neurodegener Dis Manag. 2017;7(6s):23-25. 13. Pediatric Multiple Sclerosis. Cleveland Clinic. https://my.clevelandclinic.org/ccf/media/files/Multiple_sclerosis_center.... Accessed April 19, 2019. 14. Jancic J, Nikolic B, Ivancevic N, et al. Multiple sclerosis in pediatrics: current concepts and treatment options. Neurol Ther. 2016;5(2):131-143. 15. Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017-1027. 16. Amato MP, Krupp LB, Charvet LE, et al. Pediatric multiple sclerosis: cognition and mood. Neurology. 2016;87(suppl 2):S82-S87. 17. Waldman A, Ness J, Pohl D, Chitnis T. Pediatric multiple sclerosis: clinical features and outcome. Neurology. 2016;87(9 suppl 2):S74-S81. 18. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54-59. 19. Harding KE, Liang K, Cossburn MD, et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2013;84(2):141-147. 20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. 21. Aubert-Broche B, Fonov V, Narayanan S, et al. Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology. 2014;83(23):2140-2146. 22. Kerbrat A, Aubert-Broche B, Fonov V, et al. Reduced head and brain size for age and disproportionately smaller thalami in child-onset MS. Neurology. 2012;78(3):194-201. 23. Nobis K, Bartels F, Anlar B, et al. Pediatric multiple sclerosis is associated with brain growth failure. Neuropediatrics. 2006;47. doi: 10.1055/s-0036-1583721. 24. MacAllister WS, Boyd JR, Holland NJ, et al. Neurology. 2007;68(16 suppl 2):S66-69. 25. Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M. Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol. 2011;7(2):109-122.
|